Remove Drugs Remove Pharma Companies Remove Pharmaceuticals
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

The Strategic Imperative of Out-Licensing Mature Drugs: A New Lease on Life for Legacy Assets

Drug Patent Watch

"Unlocking Hidden Value: How Out-Licensing Mature Drugs Can Breathe New Life into Legacy Assets As the pharmaceutical industry continues to grapple with patent cliffs and declining pipelines, a growing number of companies are turning to out-licensing as a strategic imperative to maximize the value of mature drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

G protein-coupled receptors (GPCRs) are a highly validated drug target family – accounting for 30-35 percent of all approved drugs. Despite this, the therapeutic potential of targeting most GPCRs remains untapped, as only 10 percent of GPCRs have been drugged.

article thumbnail

The High-Stakes Game of Pharma IP: Why Benchmarking Your Pipeline is Non-Negotiable

Drug Patent Watch

"The Pharmaceutical Industry's Best-Kept Secret: How Benchmarking Your Pipeline Can Be the Key to Unlocking Unprecedented Growth As the pharmaceutical landscape continues to evolve at breakneck speed, one thing remains constant: the importance of intellectual property (IP) in driving innovation and success.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Unlike most approved drugs, which work by turning cell signaling up or down like a dimmer switch, this approach aims to rid cells of problem proteins entirely. Earlier this year, the field got its best look yet at how well one common type of these drugs performs. Several have drugs in or near clinical testing.

article thumbnail

Valuation of Pharma Companies: 5 Key Considerations

Drug Patent Watch

"5 Key Considerations for Valuing Pharma Companies As the pharmaceutical industry continues to evolve, accurately valuing pharma companies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

Navigating the complex landscape of drug development and manufacturing can be a daunting task. The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. Ensuring Data Integrity Data integrity is paramount in pharmaceutical manufacturing.